Blar i forfatter "Fløtten, Øystein"

Viser treff 1-9 av 9

    • Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer 

      Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-08-23)
      <b>Background:</b> Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort. <br><b>Material and methods:</b> We analyzed patients ...

    • A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer 

      Grønberg, Bjørn Henning; Sjøblom, Bjørg; Wentzel-Larsen, Tore; Baracos, Vickie Elaine; Hjermstad, Marianne Jensen; Aass, Nina Kathrine; Bremnes, Roy M.; Fløtten, Øystein; Bye, Asta; Jordhøy, Marit Slaaen (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-09-25)
      Background:<br> Muscle mass and density assessed from CT-images at the L3 level are prognostic for survival and predict toxicity in cancer patients. However, L3 is not always included on routine CT-scans. We aimed to investigate whether images at the Th4 level may be used instead. <br> Methods:<br> Patients from three chemotherapy trials in advanced NSCLC were eligible (n = 1305). Skeletal muscle ...

    • Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group 

      Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Fløtten, Øystein; Aasebø, Ulf (Journal article; Tidsskriftartikkel; Peer reviewed, 2013-08-20)
      Background: The palliative role of chemoradiation in the treatment of patients with locally advanced, inoperable non-small-cell lung cancer stage III and negative prognostic factors remains unresolved.<p> <p>Methods: Patients not eligible for curative radiotherapy were randomised to receive either chemoradiation or chemotherapy alone. Four courses of intravenous carboplatin on day 1 and oral ...

    • Muscle mass and association to quality of life in non-small cell lung cancer patients 

      Bye, Asta; Sjøblom, Bjørg; Wentzel-Larsen, Tore; Grønberg, Bjørn Henning; Baracos, Vickie E.; Hjermstad, Marianne Jensen; Aass, Nina Kathrine; Bremnes, Roy M.; Fløtten, Øystein; Jordhøy, Marit Slaaen (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-05-10)
      Background<br> Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) and selected QoL outcomes in advanced non‐small cell lung cancer (NSCLC) at diagnosis.<p> Methods<br> Baseline data from patients with stage IIIB/IV NSCLC and ...

    • Pleural Empyema Caused by Streptococcus intermedius and Fusobacterium nucleatum: A Distinct Entity of Pleural Infections 

      Dyrhovden, Ruben; Eagan, Tomas Mikal Lind; Fløtten, Øystein; Siljan, William Ward; Leegaard, Truls Michael; Bø, Bjørnar; Fardal, Hilde; Grøvan, Fredrik; Kildahl-Andersen, Arne; Larssen, Kjersti Wik; Tilseth, Rune; Hjetland, Reidar; Løes, Sigbjørn Suk; Lindemark, Frode; Tellevik, Marit Gjerde; Breistein, Rebecca Irene; Kommedal, Øyvind (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-06-22)
      Background - Many community-acquired pleural infections are caused by facultative and anaerobic bacteria from the human oral microbiota. The epidemiology, clinical characteristics, pathogenesis, and etiology of such infections are little studied. The aim of the present prospective multicenter cohort study was to provide a thorough microbiological and clinical characterization of such oral-type pleural ...

    • Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer 

      Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-10-23)
      <br>BACKGROUND: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented - probably mainly due to inconvenience and concerns about toxicity. A schedule of three-week hypofractionated TRT is a commonly used alternative. This is the first randomized trial ...

    • Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement 

      Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-02)
      Background/Aim: <br>There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and <br>Methods: <br>Patients ...

    • Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer 

      Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-15)
      Objectives: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to patient referral time and the fact that TRT planning takes time. Early assessment of response to the first course of chemotherapy may be a useful way to individualise treatment. ...

    • Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group 

      Fløtten, Øystein; Grønberg, Bjørn Henning; Bremnes, Roy M.; Amundsen, Tore; Sundstrøm, Stein Harald; Rolke, Heidi; HORNSLIEN, KJERSTI; Wentzel-Larsen, Tore; Aasebø, Ulf; von Plessen, Christian (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-07-03)
      BACKGROUND: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We conducted a national, randomised study to compare a non-platinum with a platinum combination.<p> <p>METHODS: Eligible patients had stage IIIB/IV NSCLC ...